Filing Flows

Filing Flows › Companies › GoodRx Holdings › Report card

GoodRx Holdings earnings report card

Every report on file against what analysts and the company itself expected, and what the stock did

Beat rate1 of 4 reports beat the EPS estimate

GoodRx Holdings (GDRX) beat the analysts' EPS estimate in 1 of its last 4 reports (25%), by -3.9% on average. Next report: Nov 9, 2026, analysts expect EPS $0.08.

Beat rate25% of 4
Average surprise-3.9%
Next reportNov 9, 2026

Report by report

QuarterReportedEPS est.EPS reportedSurpriseGAAP EPSRevenue reported
Q2 2026Aug 5, 2026$0.08$0.08+0.4%$0.02$200M
Q1 2026May 6, 2026$0.07$0.07-2.2%$0.00$194M
Q4 2025Feb 25, 2026$0.09$0.09-1.7%—$195M
Q3 2025Nov 4, 2025$0.09$0.08-12.3%$0.00$196M

Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.

Charts

GoodRx Holdings: EPS reported against the estimateGoodRx Holdings: EPS reported against the estimateEstimateReported$0.09$0.08Q3 2025$0.09$0.09Q4 2025$0.07$0.07Q1 2026$0.08$0.08Q2 2026
Latest (Q2 2026): Estimate $0.08, Reported $0.08.

The next report: what to expect → GoodRx Holdings: every quarter →

Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.